GlassScriptPhysician profile
Buddy K Festerling
NPI 1396816567
$19,962.71
in general payments reported to CMS, 2019-2025
41 companies · $2,780 in 2025
The $2,780 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,413 · 2020: $2,711 · 2021: $4,039 · 2022: $3,742 · 2023: $2,424 · 2024: $1,853 · 2025: $2,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,004 · Education: $53.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,004.06 |
| Education | $53.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,284.59 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,241.75 | 2019-2025 | Jardiance, Tradjenta, Stiolto Respimat |
| Novo Nordisk INC | $1,768.04 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,652.39 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $1,559.80 | 2019-2025 | |
| Lilly USA, LLC | $1,177.82 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $1,084.26 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $770.27 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $706.04 | 2019-2025 | Trintellix |
| Amarin Pharma, INC. | $667.59 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $638.05 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $614.55 | 2019-2025 | Trelegy Ellipta, Nucala |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $567.42 | 2022-2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $552.64 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Merck Sharp & Dohme LLC | $522.27 | 2019-2024 | Verquvo, Belsomra, Steglatro |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Buddy Festerling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.